In the latest trading session, Acorda Therapeutics closed at $14.62, marking a +0.14% move from the previous day. This change lagged the S&P 500's 0.5% gain on the day. At the same time, the Dow added 0.54%, and the tech-heavy Nasdaq gained 0.76%.
Coming into today, shares of the drugmaker had lost 6.17% in the past month. In that same time, the Medical sector gained 2.18%, while the S&P 500 gained 2.53%.
Investors will be hoping for strength from ACOR as it approaches its next earnings release. The company is expected to report EPS of -$0.81, down 678.57% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $36.57 million, down 65.56% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$3.83 per share and revenue of $153.13 million, which would represent changes of -275.69% and -67.52%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for ACOR. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 23.32% lower within the past month. ACOR is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 78, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Image: Bigstock
Acorda Therapeutics (ACOR) Gains But Lags Market: What You Should Know
In the latest trading session, Acorda Therapeutics closed at $14.62, marking a +0.14% move from the previous day. This change lagged the S&P 500's 0.5% gain on the day. At the same time, the Dow added 0.54%, and the tech-heavy Nasdaq gained 0.76%.
Coming into today, shares of the drugmaker had lost 6.17% in the past month. In that same time, the Medical sector gained 2.18%, while the S&P 500 gained 2.53%.
Investors will be hoping for strength from ACOR as it approaches its next earnings release. The company is expected to report EPS of -$0.81, down 678.57% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $36.57 million, down 65.56% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$3.83 per share and revenue of $153.13 million, which would represent changes of -275.69% and -67.52%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for ACOR. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 23.32% lower within the past month. ACOR is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 78, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.